Traditionally, patients with newly diagnosed PTCL have been managed with chemotherapy regimens designed for aggressive B-Cell NHL, yet they generally have a poorer response to therapy and shorter survival rates compared to patients with aggressive B-Cell Lymphomas.
Data on treatment outcomes have been derived primarily from retrospective reviews, and there were no well-established standards of care overall. How patients are managed in the context of daily clinical practice, both on and off trials, was also previously unclear. Specifically, there was a lack of information regarding the factors affecting treatment decisions and whether there were differences in treatment by clinical practice setting.
Given that resources for observational Registries are typically limited - from both a site personnel and cost perspective – it was essential to partner with an eClinical/Electronic Data Capture (EDC) company that would help facilitate high-quality, cost effective and efficient data collection and management.